Bioactivity:

Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen re

CAS nr:

1420477-60-6

Purity:

98%

Molecular Weight:

465,51

SMILES:

CC#CC(=O)N1CCC[C@H]1c1nc(c2n1ccnc2N)c1ccc(cc1)C(=O)Nc1ccccn1

Formula:

C26H23N7O2

Pathway:

Tyrosine Kinase/Adaptors,Angiogenesis

Target:

BTK,BTK